ADC Therapeutics SA (ADCT) - Net Assets
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has net assets worth $-238.18 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($289.76 Million) and total liabilities ($527.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ADC Therapeutics SA (ADCT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-238.18 Million |
| % of Total Assets | -82.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | -160.4% |
| 10-Year Change | N/A |
| Growth Volatility | 137.53 |
ADC Therapeutics SA - Net Assets Trend (2016–2024)
This chart illustrates how ADC Therapeutics SA's net assets have evolved over time, based on quarterly financial data. Also explore ADCT total assets for the complete picture of this company's asset base.
Annual Net Assets for ADC Therapeutics SA (2016–2024)
The table below shows the annual net assets of ADC Therapeutics SA from 2016 to 2024. For live valuation and market cap data, see ADC Therapeutics SA stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-202.64 Million | -36.69% |
| 2023-12-31 | $-148.25 Million | -286.59% |
| 2022-12-31 | $79.45 Million | -52.16% |
| 2021-12-31 | $166.09 Million | -50.50% |
| 2020-12-31 | $335.50 Million | +201.83% |
| 2019-12-31 | $111.16 Million | -11.95% |
| 2018-12-31 | $126.24 Million | -49.33% |
| 2017-12-31 | $249.17 Million | +76.85% |
| 2016-12-31 | $140.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ADC Therapeutics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 137419100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.43 Million | % |
| Other Comprehensive Income | $-1.42 Million | % |
| Other Components | $1.28 Billion | % |
| Total Equity | $-202.64 Million | 100.00% |
ADC Therapeutics SA Competitors by Market Cap
The table below lists competitors of ADC Therapeutics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Minera Alamos Inc
V:MAI
|
$433.74 Million |
|
Zhejiang Prulde Electric Appliance Co. Ltd. A
SHE:301353
|
$433.74 Million |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
$433.83 Million |
|
Guangdong Jingyi Metal Co Ltd
SHE:002295
|
$433.84 Million |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
$433.45 Million |
|
Ganso Co Ltd
SHG:603886
|
$433.38 Million |
|
Ozak Gayrimenkul Yatirim Ortakligi AS
IS:OZKGY
|
$433.37 Million |
|
GEM Services Inc
TW:6525
|
$433.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ADC Therapeutics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -148,249,000 to -202,642,000, a change of -54,393,000.
- Net loss of 157,846,000 reduced equity.
- New share issuances of 60,506,000 increased equity.
- Other comprehensive income decreased equity by 1,328,000.
- Other factors increased equity by 44,275,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-157.85 Million | -77.89% |
| Share Issuances | $60.51 Million | +29.86% |
| Other Comprehensive Income | $-1.33 Million | -0.66% |
| Other Changes | $44.27 Million | +21.85% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares ADC Therapeutics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $4.23 | $3.50 | x |
| 2018-12-31 | $2.35 | $3.50 | x |
| 2019-12-31 | $1.66 | $3.50 | x |
| 2020-12-31 | $5.13 | $3.50 | x |
| 2021-12-31 | $2.16 | $3.50 | x |
| 2022-12-31 | $1.02 | $3.50 | x |
| 2023-12-31 | $-1.81 | $3.50 | x |
| 2024-12-31 | $-2.09 | $3.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ADC Therapeutics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -222.83%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-81.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -36.07% | -4984.03% | 0.01x | 1.09x | $-114.78 Million |
| 2018 | -97.51% | -10797.89% | 0.01x | 1.19x | $-135.72 Million |
| 2019 | -104.79% | -4977.95% | 0.02x | 1.24x | $-127.60 Million |
| 2020 | -73.41% | 0.00% | 0.00x | 1.53x | $-279.84 Million |
| 2021 | -138.50% | -678.20% | 0.05x | 3.72x | $-246.63 Million |
| 2022 | -197.77% | -74.86% | 0.43x | 6.18x | $-165.07 Million |
| 2023 | 0.00% | -345.11% | 0.20x | 0.00x | $-225.23 Million |
| 2024 | 0.00% | -222.83% | 0.22x | 0.00x | $-137.58 Million |
Industry Comparison
This section compares ADC Therapeutics SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $103,396,513
- Average return on equity (ROE) among peers: -329.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $-238.18 Million | -36.07% | N/A | $433.57 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.45 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $184.86 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $-2.99 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $627.01 Million | -44.91% | 0.25x | $3.82 Billion |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the Chi… Read more